Validation of the modified radiosurgery-based arteriovenous malformation score in a linear accelerator radiosurgery experience in Hong Kong.

The modified radiosurgery-based arteriovenous malformation (AVM) score (modified AVM score or Pollock-Flickinger AVM score [PFAS]) is a simplified grading system developed to predict outcome after gamma knife radiosurgery for cerebral AVM. The purpose of this study was to test the PFAS in a cohort of patients managed with linear accelerator (LINAC) radiosurgery. We analyzed 70 consecutive patients with cerebral AVM treated with LINAC radiosurgery in Hong Kong. The scores were determined by the following equation: Modified AVM score=(0.1×volume [cm(3)])+(0.02×age [years])+(0.5×location). The location values are as follows: hemispheric/corpus callosum/cerebellar=0; basal ganglia/thalamus/brainstem=1. A total of 74% of patients presented with ruptured AVM before radiosurgery. The overall obliteration rate was 86%. Five (7%) patients developed new permanent neurological deficits from delayed bleeding or radiation-induced complications. Modified AVM score correlated with the percentage of patients with AVM obliteration without new neurological deficits (≤1, 96%; 1.01-1.50, 78%; 1.51-2.00, 90%; >2, 50%; Spearman's rho 0.354, p=0.003). In conclusion, the modified AVM score is a good predictor of patient outcome after LINAC radiosurgery in our cohort. The modified AVM score can be used to guide treatment selection for cerebral AVM and stratify patients for future comparative analyses.

Ventricular tachycardia and ventricular fibrillation.

Ventricular tachycardia and ventricular fibrillation are the most important causes of sudden cardiac death (SCD), particularly in those with structural heart disease and reduced left ventricular function. It is important to distinguish ventricular tachycardia from supraventricular tachycardia. A wide spectrum of ventricular arrhythmias exists, from those where the heart is structurally normal to those with structural heart disease. Each entity has a distinctive pathophysiology, treatment plan and prognostic outcome. Treatment modalities include simple beta-blockade to implantation of implantable cardiac defibrillator and ablative approaches. In general, those ventricular arrhythmias associated with a structurally normal heart are more benign than those associated with structural heart disease.

Radiotherapy-induced pacemaker and implantable cardioverter defibrillator malfunction.

It is well known that ionizing radiation can interfere with circuits in permanent pacemakers and implantable cardioverter defibrillators. Contemporary implantable cardiac devices use complementary metal-oxide silicon in combination with other very sensitive transistors. These sensitive components are especially susceptible to electromagnetic and ionizing radiation, which can potentially cause permanent damage. Electromagnetic interference is, in general, a transient phenomenon. Radiologic imaging tests have been implicated in rare cases of implantable device dysfunction and these events have been mostly transient. The American Association of Physicists in Medicine last published recommendations regarding irradiation of pacemakers in 1994. This publication is outdated and may not be pertinent for the current technology used both in the field of artificial cardiac pacing and defibrillation and in the field of radiation oncology. Updated guidelines are definitely needed.

Typical atrial flutter as a risk factor for the development of atrial fibrillation in patients without otherwise demonstrable atrial tachyarrhythmias.

OBJECTIVE: To investigate the incidence of atrial fibrillation after successful radiofrequency ablation for typical atrial flutter (AFL) and to compare its incidence with that of a reference population from the Framingham Heart Study to determine whether atrial flutter is an independent predictor for development of atrial fibrillation. PATIENTS AND METHODS: Medical records of 234 patients who underwent radiofrequency ablation for AFL between January 1, 2002, and June 30, 2006, were reviewed. Patients were excluded if they had a history of atrial fibrillation or sustained atrial arrhythmia other than AFL or if they had atrial tachyarrhythmias other than AFL that could be induced during electrophysiology study (133 total patients excluded). The remaining 101 patients who underwent successful radiofrequency ablation for AFL were monitored for new-onset atrial fibrillation. RESULTS: During the mean+/-SD follow-up period of 574+/-315 days, atrial fibrillation developed in 13 (12.9%) of 101 patients. Atrial fibrillation developed in 12 of these patients within 6 months of ablation. The cumulative event-free rates (95% confidence intervals) were 97% (94%-100%) at 1 month, 91% (87%-97%) at 3 months, and 86% (81%-94%) at 6 months. Compared with the general population, patients aged 50 to 79 years who had ablation had a significantly higher incidence of atrial fibrillation (50-59 years, P=.01; 60-69 years, P=.001; 70-79 years, P=.007). CONCLUSION: Our finding of atrial fibrillation in 12.9% of patients whose atrial flutter was successfully eradicated suggests that patients with atrial flutter are at increased risk of developing atrial fibrillation, especially within the first 6 months after ablation.

Clinical use of carotid intima-media thickness: review of the literature.

Carotid intima-media thickness (CIMT) is a simple and inexpensive tool to assess the cumulative effect of atherosclerotic risk factors and is an independent predictor of future cardiovascular risk. CIMT is commonly used as a surrogate end point in research trials as a marker of atherosclerosis. However, new software programs have made CIMT a clinically practical examination for risk evaluation. CIMT correlates with cardiac risk factors and is an independent predictor of future myocardial infarction and stroke risk. Tests for subclinical atherosclerosis, such as CIMT, will help clinicians to more effectively identify the vulnerable patient who would benefit from aggressive prevention intervention.